论文部分内容阅读
2377例急性心肌梗塞(AMI)患者,于病后3～15日随机口服地尔硫(艹卓)(60mg,每6小时1次)或安慰剂。随访12～52(平均25±8)个月。全部患者中,首次AMI 1522例,包括非Q波型409例(组1),下壁Q波型664例(组2)和前壁Q波型449例(组3);有AMI史的855例(组4)。组1和2,射血分数0.52～0.54,肺充血人数10～16％;给药组心脏死亡人数少于安慰剂组。组3和4,射血分数0.38～0.44,肺充血人数24～26%;给药组心脏死亡人数多
2377 patients with acute myocardial infarction (AMI) were randomized to receive diltiazem (60 mg every 6 hours) or placebo 3-15 days after illness. Follow-up 12 ~ 52 (average 25 ± 8) months. Among all the patients, the first AMI was performed in 1522 patients, including 409 cases of non-Q wave (group 1), 664 cases of inferior Q wave (group 2) and 449 cases of anterior Q wave (group 3) Example (Group 4). Group 1 and 2, ejection fraction 0.52 ~ 0.54, the number of pulmonary congestion 10 ~ 16%; administration of cardiac deaths less than placebo group. Group 3 and 4, ejection fraction 0.38 ~ 0.44, the number of pulmonary congestion 24 ~ 26%; the number of cardiac death in the administration group and more